Harm Westdorp

1.5k citations

43 papers · 696 indexed · 1 hit paper · h-index 14

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Immunology top 10%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in ⓘ

Oncology 31
- Cancer Immunotherapy and Biomarkers 21
- Colorectal Cancer Treatments and Studies 4
Immunology 17
- Immunotherapy and Immune Responses 14

Co-authors: I. Jolanda M. de Vries (17 shared papers)Gerty Schreibelt (14 shared papers)Winald R. Gerritsen (17 shared papers)Nicoline Hoogerbrugge (6 shared papers)Carl G. Figdor (10 shared papers)Niven Mehra (15 shared papers)Sandra Heskamp (3 shared papers)Marjolijn J. L. Ligtenberg (6 shared papers)
Journals: Annals of Oncology (6 papers)Frontiers in Immunology (5 papers)Journal of Clinical Oncology (3 papers)Journal for ImmunoTherapy of Cancer (2 papers)Frontiers in Oncology (2 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Harm Westdorp

37 papers receiving 688 citations

Hit Papers

align trajectories log scale

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies 2023 · 92 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 European Journal of Nuclear Medicine and Molecular Imaging

Peers

Countries citing papers authored by Harm Westdorp

Since Specialization

Citations

This map shows the geographic impact of Harm Westdorp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harm Westdorp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harm Westdorp more than expected).

Fields of papers citing papers by Harm Westdorp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harm Westdorp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harm Westdorp. The network helps show where Harm Westdorp may publish in the future.

Co-authors

The 25 scholars most cited alongside Harm Westdorp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Harm Westdorp Line = papers co-authored together Harm Westdorp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies European Journal of Nuclear Medicine and Molecular Imaging ·Bastiaan M. Privé, Mohamed A. Boussihmad, Bart Timmermans, Willemijn A. van Gemert, Steffie M. B. Peters, Yvonne H. W. Derks, Sanne A. M. van Lith, Niven Mehra, James Nagarajah, Sandra Heskamp, Harm Westdorp Hit paper breakdown →	2023	92
2	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer Journal for ImmunoTherapy of Cancer ·Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A.J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H.J.G. Aarntzen, Roel Mus, Mareke Brüning, Katja Petry, Martin Gotthardt, Jelle O. Barentsz, I. Jolanda M. de Vries, Winald R. Gerritsen	2019	87
3	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens Frontiers in Immunology ·Harm Westdorp, Annette E. SkÃ¶ld, Berit A. Snijer, Sebastian Franik, Sasja F. Mulder, Pierre Major, Ronan Foley, Winald R. Gerritsen, I. Jolanda M. de Vries	2014	67
4	Opportunities for immunotherapy in microsatellite instable colorectal cancer Cancer Immunology Immunotherapy ·Harm Westdorp, Felix L. Fennemann, Robbert D.A. Weren, Tanya M. Bisseling, Marjolijn J. L. Ligtenberg, Carl G. Figdor, Gerty Schreibelt, Nicoline Hoogerbrugge, Florian Wimmers, I. Jolanda M. de Vries	2016	67
5	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome Cancer Letters ·Harm Westdorp, Sigrid Kolders, Nicoline Hoogerbrugge, I. Jolanda M. de Vries, Marjolijn C.J. Jongmans, Gerty Schreibelt	2017	43
6	Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment Clinical Cancer Research ·Simone C. Kleinendorst, Egbert Oosterwijk, Johan Bussink, Harm Westdorp, Mark Konijnenberg, Sandra Heskamp	2022	40
7	Immune Checkpoint Inhibitor–related Guillain-Barré Syndrome: A Case Series and Review of the Literature Journal of Immunotherapy ·Jorien B.E. Janssen, Theresa Y.S. Leow, Karin H. Herbschleb, Johanna M. M. Gijtenbeek, Marye J. Boers‐Sonderen, Winald R. Gerritsen, Harm Westdorp	2021	33
8	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation Translational Oncology ·Marc Eissing, Lise Ripken, Gerty Schreibelt, Harm Westdorp, Marjolijn J. L. Ligtenberg, Romana T. Netea‐Maier, Mihai G. Netea, I. Jolanda M. de Vries, Nicoline Hoogerbrugge	2018	32
9	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis Frontiers in Immunology ·Harm Westdorp, Mark W. D. Sweep, Mark A.J. Gorris, Frank Hoentjen, Marye J. Boers‐Sonderen, Rachel S. van der Post, Michel M. van den Heuvel, Berber Piet, Annemarie Boleij, Haiko J. Bloemendal, I. Jolanda M. de Vries	2021	31
10	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients Journal of Immunotherapy ·Steve Boudewijns, Harm Westdorp, Rutger H.T. Koornstra, Erik H.J.G. Aarntzen, Gerty Schreibelt, Jeroen H. A. Creemers, Cornelis J.A. Punt, Carl G. Figdor, I. Jolanda M. de Vries, Winald R. Gerritsen, Kalijn F. Bol	2016	30
11	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination OncoImmunology ·Steve Boudewijns, Rutger H.T. Koornstra, Harm Westdorp, Gerty Schreibelt, Alfons J.M. van den Eertwegh, Marnix H. Geukes Foppen, John B.A.G. Haanen, I. Jolanda M. de Vries, Carl G. Figdor, Kalijn F. Bol, Winald R. Gerritsen	2016	21
12	Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry Nuclear Medicine Communications ·Maike J.M. Uijen, Bastiaan M. Privé, Carla M.L. van Herpen, Harm Westdorp, Willemijn A. van Gemert, Maarten de Bakker, Martin Gotthardt, Mark Konijnenberg, Steffie M. B. Peters, James Nagarajah	2023	17
13	Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD) European Journal of Human Genetics ·Erika Leenders, Harm Westdorp, Roger J. M. Brüggemann, Jan Loeffen, Christian P. Kratz, John Burn, Nicoline Hoogerbrugge, Marjolijn C.J. Jongmans	2018	17
14	Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial Annals of Oncology ·Sandra van Wilpe, Iris S. H. Kloots, P.H.J. Slootbeek, Martijn H. den Brok, Harm Westdorp, Maïté Franken, M. Coskuntürk, Thamara E. Osinga, H. Bloemendal, Gosse J. Adema, R J Smeenk, James Nagarajah, Jolique van Ipenburg, Leonie I. Kroeze, Marjolijn J. L. Ligtenberg, J.A. Schalken, Winald R. Gerritsen, Niven Mehra	2024	14
15	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition Journal of Translational Medicine ·Jurjen Tel, Rutger Koornstra, Nienke de Haas, Vincent van Deutekom, Harm Westdorp, Steve Boudewijns, Nielka van Erp, Stefania Di Blasio, Winald R. Gerritsen, Carl G. Figdor, I. Jolanda M. de Vries, Stanleyson V. Hato	2016	11
16	Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer European Urology Oncology ·Sofie H. Tolmeijer, Sandra van Wilpe, Maartje J. Geerlings, Daniel von Rhein, Tineke J. Smilde, Iris S. H. Kloots, Harm Westdorp, M. Coskuntürk, Irma M. Oving, Jolique A. van Ipenburg, Antoine G. van der Heijden, Tom Hofste, Marjan M. Weiss, Jack A. Schalken, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra	2023	10
17	Metastatic melanoma mimicking solitary fibrous tumor: report of two cases Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Elise M. Bekers, Adriana C. H. van Engen–van Grunsven, Patricia J.T.A. Groenen, Harm Westdorp, Rutger H.T. Koornstra, Johannes J. Bonenkamp, Uta Flucke, Willeke A.M. Blokx	2014	9
18	Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial Frontiers in Immunology ·Bouke Koeneman, Gerty Schreibelt, Mark A.J. Gorris, Simone Hins - de Bree, Harm Westdorp, Petronella B. Ottevanger, I. Jolanda M. de Vries	2024	9
19	Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Frontiers in Oncology ·Jeroen H. A. Creemers, Maarten J. van der Doelen, Sandra van Wilpe, Rick Hermsen, Tjitske Duiveman‐de Boer, Diederik M. Somford, Marcel J. R. Janssen, J.P. Michiel Sedelaar, Niven Mehra, Johannes Textor, Harm Westdorp	2021	9
20	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy Clinical & Translational Oncology ·Martine Bloemendal, Mark J.A. Rietveld, Wouter W. van Willigen, Winald R. Gerritsen, Carl G. Figdor, Han J. Bonenkamp, Harm Westdorp, Steve Boudewijns, Rutger H.T. Koornstra, Eddy Adang, Gerty Schreibelt, Petronella B. Ottevanger, I. Jolanda M. de Vries, Kalijn F. Bol	2018	6

About Harm Westdorp

Harm Westdorp is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Cancer Research and Pathology and Forensic Medicine, having authored 43 papers that have together received 696 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (21 papers), Prostate Cancer Treatment and Research (15 papers), Immunotherapy and Immune Responses (14 papers), Genetic factors in colorectal cancer (7 papers), Cancer Genomics and Diagnostics (6 papers), Colorectal Cancer Treatments and Studies (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and vaccines and immunoinformatics approaches (3 papers). The work is most often cited by research in Oncology (439 citations), Immunology (255 citations), Cancer Research (112 citations), Pathology and Forensic Medicine (85 citations) and Radiology, Nuclear Medicine and Imaging (102 citations). Harm Westdorp has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include I. Jolanda M. de Vries, Gerty Schreibelt, Winald R. Gerritsen, Nicoline Hoogerbrugge, Carl G. Figdor, Niven Mehra, Sandra Heskamp, Marjolijn J. L. Ligtenberg, James Nagarajah and Bastiaan M. Privé. Their work appears in journals such as Annals of Oncology, Frontiers in Immunology, Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact